MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators.
News
Clinical Researcher of the Year – The Americas: Last chance to book
The PharmaTimes Clinical Researcher of the Year – The Americas awards ceremony & gala dinner will take place in Washington DC on Sunday at the Hyatt Regency Crystal City, presented by UK actor Ryan Philpott, who has a host of TV credits to his name, including the nation’s all time favourite, Eastenders.
International Clinical Researcher of the Year – Less than 3 weeks to go – BOOK NOW
The countdown is on! With just under three weeks to go until the 2018 PharmaTimes International Clinical Researcher of the Year Awards Ceremony, companies are advised to book now to avoid disappointment.
PharmaTimes Media announces the launch of a brand new competition for sales professionals
With rigorous entry and judging standards, the all-new Sales Awards is designed to recognise the very best sales professionals in our industry today, while offering a crucial opportunity for learning and development.
Study finds widespread belief in “mythical” causes of cancer
Research led by University College London (UCL) and the University of Leeds, with support from a Cancer Research UK/Bupa Foundation Innovation Award, has revealed widespread public belief in “mythical causes” of cancer.
Vertex to test CF triple combo therapy in Phase III trials
Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
AbbVie files risankizumab in the US
AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.
CAR-T therapy could be available to NHS patients this year
NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Lords slam government commitment to life sciences strategy
The House of Lords has slammed the government’s commitment to delivering the Life Sciences Industrial Strategy, deeming it “incoherent” and “wholly inadequate”.
Novartis app allows ophthalmology patients to report data
Novartis has launched a new app that enables patients taking part in ophthalmic clinical trials to self-report data, which could potentially speed up the development of new therapies.
NICE backs procedure for benign prostate enlargement
The National Institute for Health and Care Excellence is now endorsing a procedure called Prostate Artery Embolisation (PAE) for NHS use to treat benign prostatic hyperplasia.
Astellas files experimental AML therapy
Astellas has filed its experimental Acute Myeloid Leukemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer.
GSK reports Q1 sales decline
GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs.
Women with breast cancer risk opting out of tamoxifen therapy
The majority of women at high risk of developing breast cancer decide against prophylactic treatment with tamoxifen, suggest findings of a new study funded by Cancer Research UK and published in Breast Cancer Research and Treatment.
GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
